Additionally, clinical trials are now underway targeting the PACAP1-38 receptor, Pituitary adenylate cyclase-activating polypeptide type I receptor (PAC1R), for the prophylactic treatment of migraine. Here, ADCYAP1R1 is linked to migraine disorder.